World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

Implantica announces publication of a new health economics study showing RefluxStop®’s superior cost-effectiveness in the treatment of GERD in the Italian Healthcare System

Cision PR Newswire by Cision PR Newswire
May 21, 2026
in Press Releases - Lifestyle
Reading Time: 5 mins read
0
Share on FacebookShare on Twitter

VADUZ, Liechtenstein, May 21, 2026 /PRNewswire/ — Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces a new RefluxStop® study showing the next-gen surgical solution for GERD is highly cost-effective compared to current standard of GERD care in the Italian healthcare system.

The study titled, ‘Cost-effectiveness of RefluxStop for gastroesophageal reflux disease: analysis from an Italian healthcare perspective’ conducted by the York Health Economics Consortium in the UK and a selection of Italy’s top anti-reflux surgeons, including Prof. Davide Bona at I.R.C.C.S. Ospedale Galeazzi – Sant’Ambrogio, University of Milan, Milan, Italy, Dr. Leonardo Vincenti at IRCCS Ospedale Specializzato in Gastroenterologia Saverio de Bellis, Castellana Grotte, Puglia, Italy, Prof. Adolfo Renzi at Ospedale Buon Consiglio Fatebenefratelli, Napoli, Italy, and Prof. Luigi Bonavina at Azienda Ospedaliera di Cosenza, University of Calabria, Cosenza, Italy, was recently published in the esteemed journal, BMC Gastroenterology.

The extensive health-economic analysis shows a 100% probability that RefluxStop® is cost-effective compared with PPIs and magnetic sphincter augmentation (MSA), and a 97% probability compared with Nissen fundoplication in the Italian health system. With over 200 procedures completed and growing approval of public tenders across Italy, RefluxStop® continues to gain commercial traction, paving the way for broader reimbursement approval influencing also other European countries.

Inventor of RefluxStop® and CEO of Implantica, Dr. Peter Forsell says, “The basis for a successful launch of a new treatment always depends on good or superior clinical results, however, the power of having the most cost-effective treatment should not be underestimated. Italy is a good example where health economics with RefluxStop being the most cost-effective treatment available, goes hand in hand with securing procurement in the public healthcare system. We are grateful to the independent surgeons who choose to collect and publish RefluxStop® data, driving surgical innovation forward for GERD patients everywhere.”

Dr. Forsell continues, “With over 12 million adult GERD sufferers in Italy1, I look forward to seeing RefluxStop® deliver on its promise and make a meaningful, long-term difference for patients across Italy. Considering Ethicon’s withdrawal of the magnetic sphincter augmentation device (LINX) from Europe, Implantica is fully committed to stepping in and ensuring GERD patients have access to RefluxStop®.”

1. Zagari R, Fuccio L, Wallander M-A, Johansson S, Fiocca R, Casanova S, Farahmand B, Winchester C, Roda E, Bazzoli F. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general poplulation: the Loiano-Monghidoro study. Gut. 2008;57:1354-1359.

For further information, please contact:
Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)43 505 20 57
nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company’s Certified Adviser is FNCA Sweden AB, info@fnca.se

The information was sent for publication, through the agency of the contact person set out above, on May 21, 2026, at 08:00 a.m. (CEST).

About Implantica
Implantica is a medtech company focused on bringing advanced implantable technologies into the body to improve patient outcomes and quality of life. The company’s lead product, RefluxStop®, is a CE-marked implant for the treatment of gastroesophageal reflux disease (GERD) with the potential to transform the standard of care in anti-reflux surgery, supported by strong long-term clinical outcomes.

In addition to RefluxStop®, Implantica has developed a broad, patent-protected product pipeline partly incorporating two platform technologies: an eHealth platform designed to enable communication with and remote monitoring of implants inside the body, and a wireless energizing platform designed to wirelessly power implantable devices through intact skin. Treatment could be changed remotely, saving cost for society.

Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

About RefluxStop®
RefluxStop® is a treatment for GERD designed to address the root cause of acid reflux without compressing the food passageway.

Unlike conventional anti-reflux surgical procedures, which typically rely on encircling the esophagus and are often associated with side effects such as swallowing difficulties, inability to belch or vomit, and gas bloating, RefluxStop® restores and maintains the lower esophageal sphincter in its natural anatomical position.

The unique mechanism of action of RefluxStop® is designed to reconstruct the body’s natural anti-reflux barrier while preserving normal physiological function, offering the potential for effective reflux control with reduced side effects compared to traditional surgical approaches.

Newsroom
https://www.implantica.com/media/media-kit

Community
https://ch.linkedin.com/company/implantica
https://www.twitter.com/implantica

Media Contact:
Implantica AG
Juanita Eberhart, VP Marketing & Advocacy
M: +1 925-381-4581
juanita.eberhart@implantica.com 

This information was brought to you by Cision https://news.cision.com

https://news.cision.com/implantica/r/implantica-announces-publication-of-a-new-health-economics-study-showing-refluxstop-s-superior-cost-,c4351297

The following files are available for download:

https://mb.cision.com/Main/19732/4351297/4105437.pdf

Implantica announces publication of a new health economics study showing RefluxStop®â€™s superior cost-effectiveness in the treatment of GERD in the Italian Healthcare System

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/implantica-announces-publication-of-a-new-health-economics-study-showing-refluxstops-superior-cost-effectiveness-in-the-treatment-of-gerd-in-the-italian-healthcare-system-302778656.html

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • YeahPay targets the trust gap holding back autonomous AI shopping

    0 shares
    Share 0 Tweet 0
  • Thunes and PayerMax Deepen Strategic Collaboration to Enhance Global Payout Capabilities

    0 shares
    Share 0 Tweet 0
  • Linux Foundation Announces the Open Financial Trust Alliance to Strengthen Coordinated Protection Against Fraud, Scams and Financial Crime

    0 shares
    Share 0 Tweet 0
  • DEFSEC TECHNOLOGIES INC. COMMENTS ON NASDAQ NOTIFICATION REGARDING BID PRICE DEFICIENCY AND PROACTIVE STEPS ALREADY TAKEN TO REGAIN AND MAINTAIN COMPLIANCE

    0 shares
    Share 0 Tweet 0
  • PingPong Hits $300 Billion in Annualised Transaction Volume as APAC Surges, and Launches “Currentz” for Banks

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler